Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Beclomethasone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.76 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.76 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.62 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.98 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.98 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.98 |
| ▸ | LMNA | P02545 | 3/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.98 |
| ▸ | BLM | P54132 | 2/20 | 0.98 |
| ▸ | MAPT | P10636 | 1/20 | 0.98 |
| ▸ | GAA | P10253 | 1/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.76 |
| ▸ | PGR | P06401 | 4/20 | 0.76 |
| ▸ | AR | P10275 | 3/20 | 0.76 |
| ▸ | TSHR | P16473 | 2/20 | 0.76 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Beclomethasone SCHEMBL5486747 | 0.99 | HIF1A (1.00) | HIF1ACYP3A4NR3C1NFKB1LMNA | |
| Beclomethasone SCHEMBL13046625 | 0.99 | HIF1A (1.00) | HIF1ACYP3A4NR3C1NFKB1LMNA | |
| Beclomethasone SCHEMBL3183 | 0.99 | HIF1A (1.00) | HIF1ACYP3A4NR3C1NFKB1LMNA | |
| Beclomethasone SCHEMBL8809468 | 0.99 | HIF1A (1.00) | HIF1ACYP3A4NR3C1NFKB1LMNA | |
| Beclomethasone SCHEMBL1462741 | 0.99 | HIF1A (1.00) | HIF1ACYP3A4NR3C1NFKB1LMNA | |
| Beclomethasone SCHEMBL18762039 | 0.99 | HIF1A (1.00) | HIF1ACYP3A4NR3C1NFKB1LMNA | |
| Beclomethasone SCHEMBL5486743 | 0.99 | HIF1A (1.00) | HIF1ACYP3A4NR3C1NFKB1LMNA | |
| Beclomethasone SCHEMBL7614763 | 0.99 | HIF1A (1.00) | HIF1ACYP3A4NR3C1NFKB1LMNA | |
| Beclomethasone SCHEMBL5037573 | 0.99 | HIF1A (1.00) | HIF1ACYP3A4NR3C1NFKB1LMNA | |
| Beclomethasone SCHEMBL7755941 | 0.99 | HIF1A (1.00) | HIF1ACYP3A4NR3C1NFKB1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2704724-B1 | IMPROVED SUSPENSION FORMULATION OF BECLOMETASONE DIPROPIONATE FOR ADMINISTRATION BY INHALATION | CHIESI FARMA SPA (IT) | 2016-10-26 | — | — | EP | claimed |
| EP-2351564-B1 | Methods of treating an inflammatory-related disease | NATROGEN THERAPEUTICS INTERNATIONAL INC (US) | 2015-11-11 | — | — | EP | claimed |
| EP-1706112-B1 | METHODS OF TREATING AN INFLAMMATORY-RELATED DISEASE | NATROGEN THERAPEUTICS INTERNATIONAL INC (US) | 2014-03-12 | — | — | EP | claimed |
| EP-2464339-A2 | STEROID SOLVATES | Breath Limited (GB) | 2012-06-20 | — | — | EP | claimed |
| EP-2291176-A1 | STEROID NEBULISER FORMULATION | Breath Ltd (GB) | 2011-03-09 | — | — | EP | claimed |
| US-20110045086-A1 | Steroid Nebuliser Formulation | BREATH LTD (GB) | 2011-02-24 | — | — | US | claimed |
| WO-2011018532-A2 | STEROID SOLVATES | BREATH LIMITED (GB) | 2011-02-17 | — | — | WO | claimed |
| WO-2009127833-A1 | STEROID NEBULISER FORMULATION | BREATH LTD (GB) | 2009-10-22 | — | — | WO | claimed |
| CN-100400044-C | Combinations for the treatment of immunoinflammatory disorders | COMBINATORX INC (US) | 2008-07-09 | — | — | CN | claimed |
| CN-1599613-A | Combination therapy for the treatment of immunoinflammatory disorders | COMBINATORX INC (US) | 2005-03-23 | — | — | CN | claimed |
| EP-0820414-B1 | METERED DOSE INHALER FOR BECLOMETHASONE DIPROPIONATE | SMITHKLINE BEECHAM CORP (US) | 2004-02-04 | — | — | EP | claimed |
| EP-1073417-B1 | PHARMACEUTICAL AEROSOL FORMULATION | GLAXO GROUP LTD (GB) | 2002-12-04 | — | — | EP | claimed |
| CN-1305369-A | Pharmaceutical aerosol formulation | GLAXO GROUP LTD (GB) | 2001-07-25 | — | — | CN | claimed |
| CN-105358133-B | Composition for application to a mucosa comprising a hydroxyalkyl methylcellulose | 陶氏环球技术有限责任公司 | 2017-04-26 | — | — | CN | disclosed |
| CN-105517537-A | Composition for application to mucosa comprising cellulose ether | DOW GLOBAL TECHNOLOGIES INC | 2016-04-20 | — | — | CN | disclosed |
| CN-105358133-A | Composition for application to a mucosa comprising a hydroxyalkyl methylcellulose | DOW GLOBAL TECHNOLOGIES LLC | 2016-02-24 | — | — | CN | disclosed |
| CN-1145478-C | Medicinal aerosol formulation | — | 2004-04-14 | — | — | CN | disclosed |
| CN-1365274-A | Porous drug matrices and methods of making same | ACUSPHERE INC (US) | 2002-08-21 | — | — | CN | disclosed |
| CN-1334744-A | Medical aerosol preparation | AEROPHARM TECHNOLOGY INC (US) | 2002-02-06 | — | — | CN | disclosed |
| CN-1305369-A | Pharmaceutical aerosol formulation | GLAXO GROUP LTD (GB) | 2001-07-25 | — | — | CN | disclosed |